Aspira Women's Health Files 8-K

TL;DR

Aspira Women's Health filed an 8-K on June 11, 2025, detailing corporate events and financials.

AI Summary

Aspira Women's Health Inc. filed an 8-K on June 11, 2025, reporting other events and financial statements. The filing details the company's corporate structure and historical name changes, including its former names Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

Why It Matters

This filing provides an update on corporate events and financial reporting for Aspira Women's Health Inc., which is relevant for investors tracking the company's regulatory compliance and financial status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing primarily containing corporate information and historical data, with no immediate material financial events disclosed.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• June 11, 2025 (date) — Date of Report
• Vermillion, Inc. (company) — Former Company Name
• Ciphergen Biosystems Inc (company) — Former Company Name
• Abiotic Systems (company) — Former Company Name

FAQ

From the Filing

0001641172-25-014701.txt : 20250611 0001641172-25-014701.hdr.sgml : 20250611 20250611160542 ACCESSION NUMBER: 0001641172-25-014701 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250611 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250611 DATE AS OF CHANGE: 20250611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 251039954 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm 8-K false 0000926617 0000926617 2025-06-11 2025-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       Form 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025       Aspira Women’s Health Inc. (Exact name of registrant as specified in its charter)       Delaware   001-34810   33-0595156 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   12117 Bee Caves Road , Building III , Suite 100 , Austin , Texas   78738 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (512) 519-0400       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))       Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWHL   The OTC QB Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events.   On June 11, 2025, Aspira Women’s Health Inc. (the “Company”) issued a press release announcing that its contract with the Advanced Research Projects Agency for Health (ARPA-H) for the Sprint for Women’s Healt